Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2008 Aug 14;99(8):1679–1684. doi: 10.1111/j.1349-7006.2008.00857.x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2008 Japanese Cancer Association

PMC Copyright notice

Effects of surfactant protein (SP)‐A rescue on lipopolysaccharide (LPS)‐induced lung inflammation. (a) Mice with/without gefitinib pretreatment received intratracheal LPS instillation on day 1 and SP‐A (150 µg/kg) on days 1–3. BAL was performed on days 3 and 6 after LPS instillation. () control mice; () mice treated with gefitinib only (grey) mice treated with gefitinib and rescued by SP‐A or gefitinib+/LPS + group. Data presents means ± standard error in three mice. *P < 0.05, **P < 0.01. (b) Lung tissue (HE) 3 days after LPS instillation in the SP‐A treated group (left) and control group (gefitinib + LPS) (right).

Inline graphic — Effects of surfactant protein (SP)‐A rescue on lipopolysaccharide (LPS)‐induced lung inflammation. (a) Mice with/without gefitinib pretreatment received intratracheal LPS instillation on day 1 and SP‐A (150 µg/kg) on days 1–3. BAL was performed on days 3 and 6 after LPS instillation. () control mice; () mice treated with gefitinib only (grey) mice treated with gefitinib and rescued by SP‐A or gefitinib+/LPS + group. Data presents means ± standard error in three mice. *P < 0.05, **P < 0.01. (b) Lung tissue (HE) 3 days after LPS instillation in the SP‐A treated group (left) and control group (gefitinib + LPS) (right).